دورية أكاديمية
أعرض في EDS

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.
المؤلفون: Danese E; Division of Internal Medicine C, Department of Medicine, University Hospital of Verona, Verona, Italy., Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, Au NT, Langaee T, Siguret V, Loriot MA, Sagreiya H, Altman RB, Shahin MH, Scott SA, Khalifa SI, Chowbay B, Suriapranata IM, Teichert M, Stricker BH, Taljaard M, Botton MR, Zhang JE, Pirmohamed M, Zhang X, Carlquist JF, Horne BD, Lee MT, Pengo V, Guidi GC, Minuz P, Fava C
المصدر: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2012 Dec; Vol. 92 (6), pp. 746-56. Date of Electronic Publication: 2012 Nov 07.
نوع المنشور: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; Systematic Review
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Hoboken, NJ : Wiley
Original Publication: St. Louis : C.V. Mosby
مواضيع طبية MeSH: Coumarins/*administration & dosage , Cytochrome P-450 Enzyme System/*genetics , Polymorphism, Genetic/*genetics, Aged ; Aged, 80 and over ; Algorithms ; Alleles ; Aryl Hydrocarbon Hydroxylases/genetics ; Cohort Studies ; Coumarins/therapeutic use ; Cross-Sectional Studies ; Cytochrome P-450 CYP2C9 ; Cytochrome P450 Family 4 ; Ethnicity ; Humans ; International Normalized Ratio ; Middle Aged ; Mixed Function Oxygenases/genetics ; Publication Bias ; Sex Factors ; Vitamin K Epoxide Reductases
مستخلص: A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving 9,470 participants met prespecified inclusion criteria. As compared with CC-homozygotes, T-allele carriers required an 8.3% (95% confidence interval (CI): 5.6-11.1%; P < 0.0001) higher mean daily coumarin dose than CC homozygotes to reach a stable international normalized ratio (INR). There was no evidence of publication bias. Heterogeneity among studies was present (I(2) = 43%). Our results show that the CYP4F2 p.V433M polymorphism is associated with interindividual variability in response to coumarin drugs, but with a low effect size that is confirmed to be lower than those contributed by VKORC1 and CYP2C9 polymorphisms.
References: Physiol Genomics. 2007 Jun 19;30(1):74-81. (PMID: 17341693)
Br J Clin Pharmacol. 2010 Aug;70(2):164-70. (PMID: 20653669)
Br J Clin Pharmacol. 2010 Aug;70(2):234-40. (PMID: 20653676)
J Biomed Biotechnol. 2011;2011:739751. (PMID: 21127708)
Thromb Res. 2012 Jul;130(1):38-44. (PMID: 22192158)
Pharmacogenomics. 2009 Oct;10(10):1687-95. (PMID: 19842940)
Circulation. 2012 Apr 24;125(16):1997-2005. (PMID: 22431865)
Pharmacotherapy. 2011 Aug;31(8):785-92. (PMID: 21923605)
Clin Pharmacol Ther. 2010 Apr;87(4):417-20. (PMID: 20182420)
Blood. 2008 Apr 15;111(8):4106-12. (PMID: 18250228)
Thromb Res. 2010 Jun;125(6):e259-64. (PMID: 20421126)
Pharmacogenet Genomics. 2011 Jun;21(6):344-6. (PMID: 21451434)
Drug Metab Dispos. 2011 Aug;39(8):1433-9. (PMID: 21562147)
Drug Metab Pharmacokinet. 2011;26(2):130-6. (PMID: 21084764)
Biomedica. 2010 Jul-Sep;30(3):410-20. (PMID: 21713343)
J Thromb Haemost. 2010 May;8(5):1018-26. (PMID: 20128861)
Clin Pharmacol Ther. 2010 Jan;87(1):57-64. (PMID: 19794411)
Hum Mol Genet. 2010 Dec 1;19(23):4735-44. (PMID: 20833655)
Trials. 2010 Nov 17;11:108. (PMID: 21083927)
Pharmacogenet Genomics. 2011 Mar;21(3):130-5. (PMID: 21228733)
Pharmacotherapy. 2011 Dec;31(12):1192-207. (PMID: 22122181)
Pharmacogenet Genomics. 2009 Oct;19(10):781-9. (PMID: 19741565)
Chest. 2004 Sep;126(3 Suppl):204S-233S. (PMID: 15383473)
PLoS One. 2011;6(11):e27808. (PMID: 22114699)
Blood. 2008 Aug 15;112(4):1022-7. (PMID: 18535201)
Clin Pharmacol Ther. 2011 Oct;90(4):625-9. (PMID: 21900891)
Mol Pharmacol. 2009 Jun;75(6):1337-46. (PMID: 19297519)
Eur J Clin Pharmacol. 2009 Apr;65(4):365-75. (PMID: 19031075)
Pharmacogenet Genomics. 2010 Jul;20(7):407-13. (PMID: 20442691)
J Thromb Thrombolysis. 2010 Oct;30(3):358-64. (PMID: 20499136)
Pharmacogenomics J. 2012 Aug;12(4):312-8. (PMID: 21383771)
Hypertension. 2008 Aug;52(2):373-80. (PMID: 18574070)
Lancet. 2010 May 1;375(9725):1525-35. (PMID: 20435227)
J Hum Genet. 2011 Apr;56(4):290-5. (PMID: 21326313)
N Engl J Med. 2011 Nov 24;365(21):2002-12. (PMID: 22111719)
Thromb Res. 2010 Sep;126(3):183-90. (PMID: 20553802)
Thromb Res. 2010 Apr;125(4):e159-66. (PMID: 19942260)
Pharmacogenet Genomics. 2011 Jan;21(1):26-34. (PMID: 21063236)
Clin Pharmacol Ther. 2010 Apr;87(4):459-64. (PMID: 20072124)
BMC Med Genet. 2011 Jun 06;12:80. (PMID: 21639946)
Br J Clin Pharmacol. 2011 Sep;72(3):442-50. (PMID: 21320153)
PLoS Genet. 2009 Mar;5(3):e1000433. (PMID: 19300499)
Prostaglandins Other Lipid Mediat. 2012 Aug;98(3-4):75-85. (PMID: 22173545)
Hum Mol Genet. 2009 Oct 1;18(19):3758-68. (PMID: 19578179)
Pharmacogenomics. 2009 Feb;10(2):261-6. (PMID: 19207028)
Blood. 2009 May 14;113(20):4977-9. (PMID: 19270263)
Pharmacogenomics. 2011 Jan;12(1):15-25. (PMID: 21174619)
Thromb Haemost. 2011 Jun;105(6):1100-2. (PMID: 21475774)
Eur J Clin Pharmacol. 2011 Apr;67(4):371-381. (PMID: 21110013)
Pharmacogenomics. 2009 Dec;10(12):1905-13. (PMID: 19958090)
معلومات مُعتمدة: U01 GM074492 United States GM NIGMS NIH HHS; R01 GM068797 United States GM NIGMS NIH HHS; U01GM074492 United States GM NIGMS NIH HHS; TL1 TR000422 United States TR NCATS NIH HHS; R01GM068797 United States GM NIGMS NIH HHS; U01 GM092676 United States GM NIGMS NIH HHS; TL1 RR025016 United States RR NCRR NIH HHS; U01GM092676 United States GM NIGMS NIH HHS; TL1RR025016 United States RR NCRR NIH HHS
المشرفين على المادة: 0 (Coumarins)
9035-51-2 (Cytochrome P-450 Enzyme System)
A4VZ22K1WT (coumarin)
EC 1.- (Mixed Function Oxygenases)
EC 1.14.13.- (CYP2C9 protein, human)
EC 1.14.13.- (Cytochrome P-450 CYP2C9)
EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
EC 1.14.14.1 (Cytochrome P450 Family 4)
EC 1.14.14.78 (CYP4F2 protein, human)
EC 1.17.4.4 (VKORC1 protein, human)
EC 1.17.4.4 (Vitamin K Epoxide Reductases)
تواريخ الأحداث: Date Created: 20121108 Date Completed: 20130116 Latest Revision: 20211203
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC3731755
DOI: 10.1038/clpt.2012.184
PMID: 23132553
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-6535
DOI:10.1038/clpt.2012.184